Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
RIGEL PHARMACEUTICALS INC (RIGL)
|
Add to portfolio |
|
|
|
| Price: |
$2.74
| | Metrics |
| OS: |
173.7
|
M
| |
|
|
| Market cap: |
$476
|
M
| |
|
|
|
Net cash:
|
$18.8
|
M
| |
$0.11
|
per share
|
|
EV:
|
$457
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 120.2 | 149.2 | 108.6 | 59.3 | 44.5 | 4.5 | 20.4 | 28.9 |
| Revenue growth | -19.4% | 37.4% | 83.2% | 33.2% | 892.6% | -78.0% | -29.5% | 250.2% |
| Cost of goods sold | 1.7 | 1.1 | 0.9 | 0.9 | 0.3 | 0.0 | 0.0 | 0.0 |
| Gross profit | 118.5 | 148.2 | 107.7 | 58.4 | 44.2 | 4.5 | 20.4 | 28.9 |
| Gross margin | 98.5% | 99.3% | 99.2% | 98.5% | 99.4% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 112.5 | 91.9 | 76.6 | 74.6 | 70.0 | 37.8 | 20.9 | |
| Research and development | 60.3 | 65.2 | 60.1 | 52.9 | 46.9 | 46.3 | 63.4 | 62.8 |
| General and administrative | | | | | | | | 17.8 |
| EBITA | -54.1 | -9.0 | -29.0 | -69.1 | -72.7 | -79.6 | -64.0 | -51.7 |
| EBITA margin | -45.0% | -6.0% | -26.7% | -116.5% | -163.3% | -1775.6% | -313.8% | -179.1% |
| Amortization of intangibles | 0.1 | | | | | | | |
| EBIT | -54.2 | -9.0 | -29.0 | -69.1 | -72.7 | -79.6 | -64.0 | -51.7 |
| EBIT margin | -45.1% | -6.0% | -26.7% | -116.5% | -163.3% | -1775.6% | -313.8% | -179.1% |
| Pre-tax income | -58.6 | -17.3 | -29.7 | -66.9 | -70.5 | -78.0 | -69.2 | -51.5 |
| Income taxes | 0.0 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -58.6 | -17.9 | -29.7 | -66.9 | -70.5 | -78.0 | -69.2 | -51.5 |
| Net margin | -48.7% | -12.0% | -27.4% | -112.8% | -158.3% | -1739.3% | -339.6% | -178.1% |
| |
| Diluted EPS | ($0.34) | ($0.11) | ($0.18) | ($0.40) | ($0.44) | ($0.62) | ($0.73) | ($0.58) |
| Shares outstanding (diluted) | 172.4 | 170.5 | 168.8 | 167.4 | 160.5 | 126.3 | 94.4 | 88.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|